Compare Abbott Laboratories (ABT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs BIO-TECHNE Corp — how do they compare? Abbott Laboratories trades at $95.47 (market cap $166.94B), while BIO-TECHNE Corp trades at $70.66 (market cap $11.00B). The key difference: Abbott Laboratories is far larger — about 15.2× BIO-TECHNE Corp's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | TECH | |
|---|---|---|
Market Cap | $166.94B | $11.00B |
Sector | Health | Health |
52-Week High | $136.62 | $71.38 |
52-Week Low | $82.57 | $43.31 |
Enterprise Value | $193.69B | $11.08B |
Dividend Yield | 2.63% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Bio-Techne (TECH) trades at $70.61, down 0.3% on the day, near its $73.00 takeover offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with strong moving averages, though RSI levels indicate overbought conditions. Fundamentals reveal a high P/E of 101.29 and declining net margins, but revenue remains stable near $1.22 billion. Cash flow improved in 2025 with $10.40M net inflow, and the balance sheet holds $152.86M cash against $319M long-term debt.
Outlook is dominated by the pending acquisition, offering a clear exit at $73.00, a 3.4% premium to current price. Risks include shareholder litigation questioning deal fairness and margin pressures. Analysts are unanimously positive with no sell ratings, seeing limited downside given the buyout bid. The stock presents a low-risk opportunity if the deal closes, but investors face uncertainty from legal challenges and earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
